VIA
XENE icon

Virtus Investment Advisers’s Xenon Pharmaceuticals XENE Stock Holding History

Virtus Investment Advisers’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Buy
6,281
+93
+2% +$5.16K 0.09% 313
2026
Q1 		$360K Buy
6,188
+151
+3% +$6.96K 0.1% 256
2025
Q4 		$271K Buy
6,037
+2,568
+74% +$108K 0.07% 287
2025
Q3 		$139K Buy
3,469
+602
+21% +$21.2K 0.04% 389
2025
Q2 		$89.7K Sell
2,867
-1,294
-31% -$42.2K 0.03% 379
2025
Q1 		$140K Buy
+4,161
New +$158K 0.04% 354

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Virtus Investment Advisers's XENE Position: Q2 2026 in Review

Virtus Investment Advisers increased its Xenon Pharmaceuticals (XENE) stake by 1.5% in Q2 2026, buying an estimated $5.16K and bringing the position to 6,281 shares worth $379K. The position accounts for 0.09% of the portfolio, ranked #313.

Virtus Investment Advisers first reported a position in XENE in Q1 2025 and has held it in 6 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Virtus Investment Advisers held 6,281 shares of Xenon Pharmaceuticals worth $379K as of Q2 2026.
  • Virtus Investment Advisers bought 93 Xenon Pharmaceuticals shares in Q2 2026, an estimated $5.16K.
  • Xenon Pharmaceuticals made up 0.09% of Virtus Investment Advisers's portfolio in Q2 2026, its #313 holding.
  • Virtus Investment Advisers first reported a position in Xenon Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.